Fig. 3

Stroma components favor tumor cell motility in a miR-214-dependent manner. A–L Wound healing (A, B, E, F, G, H, I, J) or transwell (C, D, K, L) assays for mouse B16-F10 or EO771 or human MA-2 or 4175-TGL cells were pretreated for 24 h with conditioned medium (CM) or Extracellular Vesicles (EVs) derived from either miR-214^wt and miR-214^over CAFs (A, C) or MEFs (B, D) or, from either NIH3T3 mouse fibroblasts (E-H) or HS5 human bone marrow stroma cells (I-L) previously transduced with a miR-214sponge (miR-214^sponge) or an empty (control) expressing vector. M Wound healing assay for MA-2 cells pretreated for 24 h with EV-depleted Conditioned Medium (CM) or EVs derived from HS5 cells previously transduced with a miR-214sponge (miR-214^sponge) or an empty (control) expressing vector. All transwell migration assays were evaluated 18 h later; while wound healing motility assays were evaluated 6 h (B16-F10)—18 h (EO771, MA-2)—24 h (4175-TGL) later. All results are shown as mean ± SEM and respectively shown as mean ± SEM of the area (pixels) or distance/time (μm/h of 10 pictures/duplicates) covered by migrated cells. For (A, B, E, F, G, H; I, J, M) experiments were performed at least twice as duplicates and pooled results of two or three experiments are shown. For (C, D, K, L) experiments were performed as triplicates and representative experiments are shown. CAFs = cancer associated fibroblasts; MEFs = murine embryo fibroblasts; SEM = standard error of mean. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001